Building data and intelligence capabilities to provide evidence of impact for the profession

Cryo-electron microscopy (cryoEM) is a Nobel Prize-winning technique for solving high-resolution three-dimensional structures of biological molecules such as proteins, that is used for structure-based drug design. Key to the success of cryoEM are significant advances in high performance computer vision and machine learning algorithms, used to extract information from large numbers of noisy 2D microscope images and compute and refine 3D structures of target proteins in near-native states.

Various aspects of the pharma sourcing process and supplier relationships offer opportunities to advance sustainability and strategic goals. These include alternative raw materials at manufacturing facilities (e.g., biomass and recycled plastic), sourcing of renewable materials (e.g., palm oil), partnering on supplier sustainability, and more.For example, BASF has seen sustainable sourcing begin to matter more for pharma, with a number of pharma companies taking a proactive role, because:

Join this webinar to discover the advantages of using Signatura™ (RUO), a novel assay custom-designed for each patient that detects circulating tumour DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumours. Learn about the latest clinical data for Signatura and explore how this unique ctDNA assay can be applied in pharmaceutical development and oncology clinical study design, potentially increasing the probability of trial success, reduce the time to trial readout, and decrease clinical trial costs

Datamonitor Healthcare’s Pharmavitae Analytics team casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals.